Chronic, recurrent Lymphocytic Leukemia Active Not Recruiting Phase 1 Trials for Nivolumab (DB09035)

Also known as: Recurrent Chronic Lymphocytic Leukemia

IndicationStatusPhase
DBCOND0112002 (Chronic, recurrent Lymphocytic Leukemia)Active Not Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01822509Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell TransplantTreatment